Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
BOSTON, May 30, 2017 -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced it will webcast its corporate presentation at the Jefferies 2017 Healthcare Conference in New York City on Tuesday, June 6, 2017 at 1:30 p.m. Eastern Time.
A live audio webcast of the presentation will be accessible from Keryx’s website at http://investors.keryx.com within the Investor Relations section under “webcasts and presentations.” An archived version of the webcast will be available for at least 15 days following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., with headquarters in Boston, Massachusetts, is a commercial stage company focused on bringing innovative medicines to people with renal disease. Keryx developed and commercializes Auryxia® (ferric citrate) in the U.S. Ferric citrate is marketed as Riona® by Keryx’s Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex). Keryx has programs underway to leverage its development and commercial infrastructure, including potentially expanding the indication of Auryxia and in-licensing medicines for renal disease. For more information about Keryx, please visit www.keryx.com.
KERYX BIOPHARMACEUTICALS CONTACT: Lora Pike Senior Director, Investor Relations & Corporate Communications T: 617-466-3511 [email protected]
